Comparison of intravenous Magnesium Sulphate with intrathecal Magnesium Sulphate for post-operative analgesia in orthopaedic patients undergoing extracapsular hip fracture surgery

Arvind Kumar1*, Usha Kumari Chaudhary2, Dinesh Kansal1, Shelly Rana2, Vipin Sharma3, Parbeen Kumar1

ABSTRACT

Background: Magnesium sulphate (MgSO4) N methyl D aspartate receptor antagonist has the potential to be an ideal adjuvant for postoperative analgesia via intrathecal or intravenous route. The aim of the study was, we compared the efficacy of two routes of MgSO4 (Intravenous vs intrathecal) as an adjuvant to bupivacaine in subarachnoid block (SAB).

Methods: Ninety, American Society of Anesthesiologists physical status 1 or 2 patients, aged 20-60 years, scheduled for hip surgeries under SAB were recruited in department of Anaesthesia and Dept. of Orthopaedics. Patients in group 1 (n=29) received intrathecal 0.5% (H) bupivacaine 15 mg with 0.1 ml of normal saline and 250 ml 0.9% normal saline intravenous 30 minutes before giving SAB. Group 2 (n=30) patients received intrathecal 0.5% bupivacaine 15mg with 0.1 ml of normal saline and 50mg/kg of magnesium sulphate in 250 ml normal saline intravenous 30 minutes before giving SAB. In Group 3 (n=30) patients received intrathecal 0.5% (H) bupivacaine 15 mg with 50mg (0.1ml) magnesium sulfahte and 250 ml 0.9% normal saline intravenous 30 minutes before giving SAB. They were evaluated for block characteristics, visual analogue scale at various time intervals up to 24 hours and total rescue analgesic and duration of postoperative analgesia were noted.

Results: Intravenous magnesium sulphate had maximum pain free interval, lower pain scores, longer sensory and motor blockade and less requirement of rescue analgesia as compared to the patients in intrathecal group or control group (P<0.05).

Conclusions: Intravenous magnesium sulphate was more effective as compared to intrathecal route with regards to the pain scores and in providing postoperative analgesia.

Keywords: Adjuvants, Anesthesia, Analgesia, Magnesium Sulfate, Pain, Postoperative

INTRODUCTION

Magnesium sulphate has been reported to be effective in perioperative pain treatment by virtue of its antagonist effect on NMDA receptors. Although magnesium is not a primary analgesic in itself, it enhances the analgesic actions of local anaesthetics as an adjuvant. Antinociceptive effects of magnesium appear to be relevant not only to chronic pain, but it also determines, in part, the duration and intensity of postoperative pain. Numerous clinical investigations have demonstrated that Mg infusion during general anaesthesia reduces anaesthetic requirement and postoperative analgesic consumption, whereas other studies suggested that perioperative IV (intravenous) Mg administration had little effect on postoperative pain.

It is likely that intrathecal magnesium sulphate potentiates spinal anaesthesia by a localized action on spinal nociceptive pathways, explaining the absence of central side-effects after systemic administration of large
doses of magnesium. As intrathecal magnesium alone has been shown to induce sensory and motor block. It is expected that magnesium might potentiate the spinal block due to a synergistic interaction between NMDA antagonists and LA (local anesthetic). The efficacy and safety of intrathecal magnesium sulphate is reported in rats and human in earlier studies. Till date single study has compared the effect of the intravenous and intrathecal magnesium on the postoperative pain and suggested that co-administration of intravenous Mg sulphate or intrathecal Mg given to patients undergoing spinal anaesthesia for total hip arthroplasty could improve pain control for the first 24h after surgery. While there was no significant difference between the two modalities as regard pain scores, however, IV magnesium led to relative hypotension and decreased blood loss. Further studies are still needed to verify these results.

Therefore, we planned a study to compare the analgesic efficacy of intravenous magnesium sulphate versus intrathecal magnesium as an adjuvant to bupivacaine, in patients scheduled for extracapsular hip surgeries under spinal anaesthesia.

METHODS

After approval by Institutional Ethics Committee (HFW-H-DRPGMC/Ethics/2014/39) and CTRI registration (CTRI/2015/06/005923), a prospective, randomized controlled, double blind study was carried out on 90 patients of both sexes in the age group of 20-60 years over a period of 18 months. Patients were ASA I-2, scheduled for lower limb surgeries under subarachnoid block. Patients refusal for spinal anaesthesia, having bleeding diathesis, uncontrolled and labile hypertension, allergy to any of the study drugs and BMI >40 kg/m² were exclusion criteria.

The patients were randomly allocated to one of the three groups by random number chart. Randomization was done by computer generated randomized number table. Random number was enclosed in a sealed opaque envelope and was opened by one of investigator to know the study drug/combination to be administered, only after shifting of patient inside operation theatre. Observer who collected postoperative data was blinded to the test drug/combination administered through intravenous and intrathecal route.

The anaesthetic procedure was explained to the patients enrolled for the study and thereafter written consent was taken. All patients were given ringer lactate at the rate of 10 ml/kg/hour before the procedure for preloading. Standard monitoring of ECG, NIBP and pulse oximetry was attached. All patients in three groups received 250 ml of drug solution 30 minutes before subarachnoid block as per allocation. After aseptic skin preparation and sterile draping, lumbar puncture was done at the level of L₂-L₄ vertebra with 26 G Quincke’ spinal needle in lateral position and 3.1 ml of study drug solution was given after confirming the free flow of CSF.

Three groups received the pre mixed coded solutions per randomization. Group 1 (n=30) patients received intrathecal 0.5% heavy bupivacaine 15 mg (Anawin *Heavy, Neon Laboratories limited, Palghar, M.S.) with 0.1 ml of normal saline and 250 ml 0.9% normal saline intravenous 30 minutes before giving subarachnoid block. Group 2 (n=30) patients received intrathecal 0.5% heavy bupivacaine 15mg (3ml) with 0.1 ml of normal saline and 50mg/kg of magnesium sulphate (Magneon,50% v/w, total volume 2ml by Neon Laboratories limited, Mumbai)in 250 ml normal saline intravenous 30 minutes before giving subarachnoid block. In Group 3 (n=30) patients received intrathecal 0.5% (H) bupivacaine 15 mg (3ml) with 50mg (0.1ml) magnesium sulphate and 250 ml 0.9% normal saline intravenous 30 minutes before giving subarachnoid block.

After placing the patient in supine position, the sensory level was assessed by pinprick sensation using a blunt 25G needle along the midclavicular line bilaterally at 3, 6, 9, 12, 15, 20, 25 and 30 min. and then every 15 min. The time to reach the sensory level up to T10 dermatome and maximum sensory level, the time for two segment regression and to S1 segment regression recorded. The motor level was assessed according to modified Bromage scale to know the time to reach Bromage level 1 and the time to Bromage 5 regression.

All patients were monitored intraoperatively for systolic, diastolic, mean blood pressure, heart rate, oxygen saturation and respiratory rate every 1 minute for first 10 minute and then every 5 min for half an hour and then every 15 minute till the end of surgery in operating room and also in recovery room. Any hypotension (SBP <90 mmHg) episode was treated with injection mephentermine 6 mg bolus and episodes of bradycardia (HR <40 beats/min) were treated with intravenous atropine 0.02 mg/kg. Postoperatively patients were observed for vitals and pain in the recovery room and then in the postsurgical ward for 24 hrs.

Severity of pain was measured using a 10 point visual analogue scale (VAS) at hourly interval for next 6 hours after subarachnoid block and then at 8th, 10th, 12th, 15th, 18th and 24th hour. The postoperative rescue analgesia was provided by inj. diclofenac sodium 75 mg IM (intramuscular) (VAS >3). Block characteristics and duration of analgesia were the primary outcome, whereas number of rescue analgesics required and intraoperative haemodynamic parameters was the secondary outcomes.

Data was collected and entered in MS Excel 2007. Parametric data like heart rate, BP were compared and analysed by Kruskal-Wallis test whereas non-parametric data such as VAS, rescue analgesics were analysed by Mann-Whitney U test and Chi-square test. The Bonferroni correction was used to correct for multiple
testing at different time points. Time for first rescue analgesic medication was analysed using survival analysis and Cox-regression analysis. A value of p < 0.05 was considered significant.

After approval by Institutional Ethics Committee (HFW-H-DRPGMC/Ethics/2014/39) and CTRI registration (CTRI/2015/06/005923), a prospective, randomized controlled, double blind study was carried out on 90 patients of both sexes in the age group of 20-60 years over a period of 18 months. Patients were ASA I-2, scheduled for lower limb surgeries under subarachnoid block. Patients refusal for spinal anaesthesia, having bleeding diathesis, uncontrolled and labile hypertension, allergy to any of the study drugs and BMI >40 kg/m² were exclusion criteria. The patients were randomly allocated to one of the three groups by random number chart. Randomization was done by computer generated randomized number table. Random number was enclosed in a sealed opaque envelope and was opened by one of investigator to know the study drug/combination to be administered, only after shifting of patient inside operation theatre. Observer who collected postoperative data was blinded to the test drug/combination administered through intravenous and intrathecal route.

The anaesthetic procedure was explained to the patients enrolled for the study and thereafter written consent was taken. All patients were given ringer lactate at the rate of 10 ml/kg/hour before the procedure for preloading. Standard monitoring of ECG, NIBP and pulse oximetry was attached. All patients in three groups received 250 ml of drug solution 30 minutes before subarachnoid block as per allocation. After antiseptic skin preparation and sterile draping, lumbar puncture was done at the level of L₃-L₄ vertebra with 26 G Quincke’ spinal needle in lateral position and 3.1 ml of study drug solution was given after confirming the free flow of CSF.

Three groups received the pre mixed coded solutions per randomization. Group 1 (n=30) Patients received intrathecal 0.5% heavy bupivacaine 15 mg (Anawin *Heavy, Neon Laboratories limited, Palghar, M.S.) with 0.1 ml of normal saline and 250 ml 0.9% normal saline intravenous 30 minutes before giving subarachnoid block. Group 2 (n=30) patients received intrathecal 0.5% heavy bupivacaine 15mg (3ml) with 0.1 ml of normal saline and 50mg/kg of magnesium sulphate (Magneon, 50%/v/w, total volume 2ml by Neon Laboratories limited, Mumbai)in 250 ml normal saline intravenous 30minutes before giving subarachnoid block. In Group 3 (n=30) patients received intrathecal 0.5% (H) bupivacaine 15 mg (3ml) with 50mg (0.1ml) magnesium sulphate and 250 ml 0.9% normal saline intravenous 30 minutes before giving subarachnoid block. After placing the patient in supine position, the sensory level was assessed by pinprick sensation using a blunt 25G needle along the midclavicular line bilaterally at 3, 6, 9, 12, 15, 20, 25 and 30 min. and then every 15 min. The time to reach the sensory level up to T10 dermatome and maximum sensory level, the time for two segment regression and to S1 segment regression recorded. The motor level was assessed according to modified Bromage scale to know the time to reach Bromage level 1 and the time to Bromage 5 regression.

All patients were monitored intraoperatively for systolic, diastolic, mean blood pressure, heart rate, oxygen saturation and respiratory rate every 1 minute for first 10 minute and then every 5 min for half an hour and then every 15 minute till the end of surgery in operating room and also in recovery room. Any hypotension (SBP < 90 mmHg) episode was treated with injection mephentermine 6 mg bolus and episodes of bradycardia (HR<40 beats/min) were treated with intravenous atropine 0.02 mg/kg. Postoperatively patients were observed for vitals and pain in the recovery room and then in the postsurgical ward for 24 hrs.

Severity of pain was measured using a 10 point visual analogue scale (VAS) at hourly interval for next 6 hours after subarachnoid block and then at 8th, 10th, 12th, 15th, 18th and 24th hour. The postoperative rescue analgesia was provided by inj. diclofenac sodium 75 mg IM (intramuscular) (VAS >3). Block characteristics and duration of analgesia were the primary outcome, whereas number of rescue analgesics required and intraoperative haemodynamic parameters was the secondary outcomes.

Data was collected and entered in MS Excel 2007. Parametric data like heart rate, BP were compared and analysed by Kruskal-Wallis test whereas non-parametric data such as VAS, rescue analgesics were analysed by Mann-Whitney U test and Chi-square test. The Bonferroni correction was used to correct for multiple testing at different time points. Time for first rescue analgesic medication was analysed using survival analysis and Cox-regression analysis. A value of p<0.05 was considered significant.

RESULTS

After approval of institution ethics committee and CTRI registration, ninety patients were included in the study and randomly divided into three groups (Figure 1). Patients in the three groups were comparable with regard to age, BMI, ASA status and duration of surgery (Table 1).

The time taken to reach T10 segment was comparable in three groups 1, 2 and 3 (2.55±1.055, 2.900±1.46 and 3.000±1.856: P=0.488) minutes respectively (Figure 2). The time to achieve peak sensory level was (mean±SD: 4.320±1.266, 2.900 ±1.464 and 3.000±1.856) min. in group 1, 2 and 3 respectively (P=0.092). Similarly the time taken to reach Bromage 1 was also comparable in all the three groups (mean±SD: 3.286±1.019, 3.416±1.414 and 3.900±2.350: P=0.384) min. in groups 1,2 and 3 (Figure 2).
Figure 1: Patients recruited and analyzed in three groups.

Table 1: Demographic data.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Group 1 control group (n = 29)</th>
<th>Group 2 IV group (n = 30)</th>
<th>Group 3 IT group (n = 30)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (Years)</td>
<td>52.66±8.776</td>
<td>51.13±9.413</td>
<td>49.57±11.057</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>61.93±6.491</td>
<td>58.23±6.663</td>
<td>57.10±7.810</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>156.21±6.383</td>
<td>154.20±7.989</td>
<td>156.90±6.294</td>
</tr>
<tr>
<td>BMI (Kg/m²)</td>
<td>25.157±2.445</td>
<td>24.390±2.983</td>
<td>23.530±3.185</td>
</tr>
<tr>
<td>ASA Status (I/ II)</td>
<td>29/ 0</td>
<td>28/2</td>
<td>28/2</td>
</tr>
<tr>
<td>Duration of surgery (min.)</td>
<td>105.17±32.26</td>
<td>94.72±19.94</td>
<td>103.31±31.43</td>
</tr>
</tbody>
</table>

Value expressed as mean ± SD
Expressed as number of patients in each group and analyzed by Chi square test.


The total duration of sensory block defined as regression to S1 segment was (104.89±27.01, 135.13±36.79 and 129.4±34.80: P=0.001, group 1 and 2: P=0.002 and group 1&3: P=0.01) minutes in group 1, 2 and 3 respectively. The duration of motor block taken as time to Bromage 5 regression was (174.06±66.85, 208.46±54.735 and 176.30±45.841: P=0.035, group 1 and 2: P=0.03 and group 2 and 3: P=0.02) minutes in groups 1, 2 and 3 respectively (Figure 3).

Pain free interval was defined as time interval between administration of test drug and the first rescue analgesic was (237.07±89.52, 317±116.2 and 268.28±104.93: P=0.008, group 1, 2: P=0.04) minutes in group 1, 2 and 3 respectively (Figure 3). There was significant decrease in the visual analogue score (VAS) in intrathecal and intravenous group as compared to control group (Figure 4). The pain score was less in intravenous group at all intervals except 4th hr, 12th hr, 15th hr and 24th hr postoperatively as compared to the control group. The pain score was also less at 1st, 2nd and 8th hr in intravenous group as compared to the intrathecal group (P=0.04). The pain scores were less in intrathecal group as compared to the control group at 1st, 5th, 6th, 10th, 15th and 18th hour (P=0.002). The rescue analgesic requirement was significantly less in intravenous group and intrathecal group as compared to control group (P=0.012). The total rescue analgesic requirement was 147.41±24.40, 122.50±36.76 and 134.48±30.91: P=0.012, groups 1 and 2: P=0.009) mg in groups 1, 2 and 3 respectively (Figure 5).

Intraoperative heamodynamics including heart rate, diastolic, mean and systolic blood pressure and peripheral oxygen saturation were comparable in three groups at all study interval time periods and did not require any intervention.

**DISCUSSION**

Recent years have witnessed increased interest in perioperative pain management with the aim enhancing dynamic restoration of functions especially after orthopaedic surgery. Good postoperative analgesia is associated with improved outcome in terms of reduction in opioid consumption, early mobility and decreased hospital stay.

Magnesium have been very widely used as pre-emptive analgesia, so we therefore planned a study to compare the effects of magnesium sulphate as a pre-emptive analgesic either through intravenous route given preoperatively.
prior to subarachnoid block or as an adjuvant to intrathecal bupivacaine. Hypothesis was that magnesium sulphate prolongs the duration of motor and sensory block and also prolongs the time to first analgesia when given via either of the two routes as compared to the control.

We have used magnesium sulphate in the single bolus dose of 50mg/kg given over a period of 30 minutes prior to subarachnoid block in accordance to study done by Kiran S and colleagues. They concluded that preoperative magnesium sulphate infusion decreases postoperative pain and requirement of rescue analgesia. Similarly, in the meta analysis by Albrecth and colleagues it is suggested that a single bolus administration of magnesium sulphate between 40 and 50 mg/kg reduces postoperative morphine consumption. 

The dose of intrathecal magnesium used in this study was based on data from Buvendraan et al, where 50 mg of spinal magnesium sulphate potentiated fentanyl anti-nociception. Intrathecal magnesium sulphate potentiates spinal anaesthesia by a localized action on spinal nociceptive pathways, explaining the absence of central side-effects after systemic administration of large doses of magnesium. As intrathecal magnesium alone has been shown to induce sensory and motor block, it is presumed that magnesium might potentiate the spinal block due to a synergistic interaction between local anaesthetics and NMDA antagonists.

In our study the onset time for peak sensory block (T6) was prolonged in IV group (5.40±2.40 min.) as compared to intrathecal group (5.300±2.306 min.) and control group (4.32±1.266 min.) (P= 0.143). Time to Bromage 1 was also more in intrathecal group (3.90±2.55min) as compared to IV group (3.416±1.141 min.) as well as control group (3.286±1.019 min) (p=0.781). These results are in accordance with the results by Samir et al., wherein the onset of sensory (T10) block was (4.78±0.78 min. 4.97±0.74 min, 5.0±0.69 min; p= 0.549) in control, intrathecal and intravenous groups respectively. Similarly the onset of motor block was (7.68±0.70 min, 6.72±2.97 min, 7.3±0.80 min; p=0.128) in control, intrathecal and intravenous groups respectively. The increased time taken in their study might be because of different end point taken as onset of motor block (Bromage 3) in comparison to Bromage 1 in our study. Secondly they have combined fentanyl to intrathecal LA and magnesium.

We observed that the administration of magnesium via either route prolongs the duration of motor and sensory blockade. The duration of sensory block was increased in intravenous group (135.655±37.333min.) as well as in intrathecal group (129.379±33.662 min.) as compared to the control group (104.896±27.011min: P=0.001). The duration of motor block was (173.14±67.89min, 209.78±56.42 min. and 175.10±47.23 min: P=0.033) in control, IV magnesium and intrathecal magnesium groups respectively.

Similar results were observed by Samir et al who found that the sensory blockade was maximum in intravenous group (303.7±21.77 min.) as compared to intrathecal group (299.7±18.31min.) and control group (227.1±16.26: P=0.001), but this difference was not statistically significant between intravenous and intrathecal group. Motor block was (198.1±24.03 min.) in intravenous group as compared to the intrathecal group (200.4±11.81min.) and control group (193.88±21.41min.) (p=0.66). The discrepancy in the motor duration in the IV and IT magnesium may be because of addition of intrathecal fentanyl.

However in the study by Kumar et al, the authors observed that duration of sensory block (237.10±37.19, 242.80±23.88: P=0.48) min and motor block (287.87±31.61, 270.40±24.87: P=0.39) minutes in magnesium and control groups were comparable. The timing of magnesium sulphate infusion might be the contributing factor as it was started just prior to spinal block in this study, whereas in our study the single bolus infusion was started thirty minutes prior to subarachnoid block.

In the present study patients in intravenous group were pain free for longest period (317±116.21 min) as compared to intrathecal (268.28±104.93 min) and control (237.07±89.52min) groups. The rescue analgesic requirement was also least in the intravenous group (122.50±36.76 mg) as compared to intrathecal (134.48±30.9 mg) and control (147.41±24.4mg: P=0.012). The pain free period in the study by Samir EM et al was maximum in the intravenous and intrathecal group as compared to the control group. The difference between the intrathecal group and intravenous group was also statistically significant. This was in accordance with our study, however the duration of the pain free period was less in this study as compared to our study which can be due to the use of lower dose of bupivacaine in their study (2.4 -3.0 mg). The requirement of rescue analgesia was maximum in the control group as compared to the intravenous group and intrathecal group in the form of injection meperidine. This difference between the intravenous group and the intrathecal group was not statistically significant.

Similarly, Kumar M and colleagues studied sixty patients who underwent spinal anaesthesia with bupivacaine and received infusion magnesium sulphate prior to subarachnoid block and concluded that the maximum pain free period was more in the group receiving magnesium infusion (333.91±202.41 min). as compared to control group (232.68±140.62) minutes (P=0.04).
Analgesic consumption and pain scores at rest have not been related with central sensitization but it has to do with wind-up phenomenon and hyperalgesia. Lower concentrations of magnesium may interact with N-type calcium channel activity that mediates pain signalling. N-type calcium channels are highly concentrated in the synaptic terminals they make in the dorsal horn of the spinal cord (laminae I and II). These primary afferents (mainly C-fibers and Aδ-fibers) are implicated in the sensation of a variety of noxious painful stimuli. Block of high voltage-gated N-type calcium channel currents dramatically inhibits the release of neuropeptides as substance P and calcitonin generated peptides from sensory neurons.

In our study the postoperative VAS pain scores were lower in group 2 and group 3 as compared to the control group at 1st, 2nd, 3rd, 5th, 6th, 8th, 10th, 15th and 18th hour (P=0.002) however there was significant difference at 1st and 2nd hour in intrathecal vs intravenous group. Our results are in accordance with study by Samir et al. The VAS score was significant at 1st, and 2nd, 6th, 12th and 24th hour similar to our study. The VAS Score was significantly less in intravenous and intrathecal group as compared to control group, but there was no statistical significance between these two groups.

All the patients were haemodynamically stable intraoperatively in all three groups and no intervention was required.

Our data showed that the patients who received intravenous magnesium sulphate had maximum pain free interval, lower pain scores, longer sensory and motor blockade and less requirement of rescue analgesia as compared to the patients in intrathecal group or control group. All the patients were comfortable in the postoperative period. Thus we concluded that magnesium sulphate prolongs the postoperative analgesia with minimum side effects when given through either intravenous or intrathecal route.

The study has few limitations such as we did not measure the serum and CSF Mg++ levels preoperatively and in postoperative period due to some technical reasons. The measurement of the Mg++ levels could have helped us in better correlation of serum magnesium concentration with the pain free period in intravenous group and also we could have ascertained any correlation between the CSF Mg++ levels and the analgesic effects in the intrathecal group the measurement of serum magnesium concentration after study drug administration was not done, which could have been more informative. Therefore further studies are required in this regard.

CONCLUSION

Thus we concluded that magnesium sulphate prolongs the postoperative analgesia with minimum side effects when given through either intravenous or intrathecal route. However intravenous magnesium sulphate was more effective as compared to intrathecal route with regards to the pain scores and in providing postoperative analgesia.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: The study was approved by the Institutional Ethics Committee

REFERENCES

12. Buvanendran A, McCarthy RJ, Kroin JS, Leong W, Perry P, Tuman KJ. Intrathecal magnesium prolongs...